LOW GRADE GLIOMA

This study tests a precise type of radiation called proton therapy for people with low-grade or certain grade 3 brain tumors (gliomas). The goal is to see if it can control tumor growth as well as standard radiation while causing fewer side effects by sparing healthy brain tissue…

This study tests a daily oral drug called trametinib in children and young adults (ages 1 month to 25 years) with certain brain or nerve tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or stop them from growing. The study inclu…

This early-stage trial is testing the safety and best dose of two drugs, trametinib and everolimus, given together to children and young adults whose gliomas (a type of brain tumor) have come back after previous treatment. The study aims to find the highest dose that is safe and …

This study tests whether a targeted drug called selumetinib works as well as or better than standard chemotherapy (carboplatin/vincristine) for children and young adults (ages 2–21) with NF1-related low-grade gliomas. The goal is to control tumor growth and improve vision in thos…

This phase 2 trial tests whether the immunotherapy drug nivolumab can stop or slow the growth of IDH-mutant gliomas, a type of brain tumor. The study includes 62 adults whose tumors have a high number of mutations (hypermutator phenotype) or not. Participants receive nivolumab in…

This early-phase trial enrolls 16 adults with recurrent IDH-mutant gliomas who are scheduled for surgery. Participants take niraparib for about a month before their operation so researchers can measure how much drug reaches the tumor and how it affects cancer cells. The goal is t…